A Novel Anti-nucleocapsid Antibody Avidity Method for Identifying SARS-CoV-2 Reinfections

被引：3
|
作者：
Golding, Liam [1 ,2 ]
Watts, Allison W. [1 ]
Shew, Jacob [1 ,2 ]
Paramo, Marina Vineta [1 ,2 ,3 ]
Masse, Louise C. [1 ,4 ]
Goldfarb, David M. [1 ,5 ]
Abu-Raya, Bahaa [1 ,2 ]
Lavoie, Pascal M. [1 ,2 ,3 ,6 ]
机构：
[1] Univ British Columbia, British Columbia Childrens Hosp Res Inst, Vancouver, BC, Canada
[2] Univ British Columbia, Fac Med, Dept Pediat, Vancouver, BC, Canada
[3] Univ British Columbia, Dept Obstet & Gynecol, Women & Childrens Hlth, Vancouver, BC, Canada
[4] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada
[5] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada
[6] British Columbia Childrens Hosp Res Inst, 950 West 28th Ave, Vancouver, BC, Canada
来源：
JOURNAL OF INFECTIOUS DISEASES | 2024年 / 230卷 / 03期
关键词：
SARS-CoV-2; COVID-19; avidity; serology; nucleocapsid; reinfection;
D O I：
10.1093/infdis/jiae072
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections is challenging with current serology assays and is further complicated by the marked decrease in routine viral testing practices as viral transmission increased during Omicron. Here, we provide proof-of-principle that high-avidity anti-nucleocapsid (N) antibodies detects reinfections after a single infection with higher specificity (85%; 95% confidence interval [95% CI], 80%-90%) compared to anti-N antibody levels (72%; 95% CI, 66%-79%) in a vaccinated cohort. This method could be used to retroactively investigate the epidemiology and incremental long-term health consequences of SARS-CoV-2 reinfections. Measuring the high-avidity anti-nucleocapsid (N) IgG detected SARS-CoV-2 reinfections after de novo infection with improved specificity compared to anti-N IgG levels. This method allows retroactive study of the epidemiology and health consequences of asymptomatic or unreported reinfections.
引用
收藏
页码：e579 / e583
页数：5
相关论文
共 50 条
  • [21] Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022
    Bratcher, Anna
    Jones, Jefferson M.
    Meyer, William A., III
    Waheed, Rehan
    Yazgi, Huda
    Harris, Aaron
    Gundlapalli, Adi V.
    Clarke, Kristie E. N.
    PLOS ONE, 2025, 20 (01):
  • [22] Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody
    Terry, James S.
    Anderson, Loran BR.
    Scherman, Michael S.
    McAlister, Carley E.
    Perera, Rushika
    Schountz, Tony
    Geiss, Brian J.
    VIROLOGY, 2021, 558 : 28 - 37
  • [23] Kinetics of Neutralizing Antibodies (nAb) SARS-CoV-2 and Anti-Nucleocapsid (NP) Antibodies in Convalescent Plasma Donors.
    Wendel, Silvano
    Fontao-Wendel, Rita
    Fachini, Roberta
    Candelaria, Gabriela
    Scuracchio, Patricia
    Achkar, Ruth
    Guaragna Machado, Rafael Rahal
    Araujo, Danielle
    Soares, Camila Pereira
    Durigon, Edison
    TRANSFUSION, 2020, 60 : 290A - 290A
  • [24] SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection
    Hoyois, A.
    Gulkilik, C.
    Mekkaoui, L.
    Dahma, H.
    Wambacq, V.
    Minsar, C.
    Rosewick, N.
    Liefferinckx, C.
    Amininejad, L.
    Van Gossum, A.
    Cremer, A.
    Vandenberg, O.
    Franchimont, D.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2024, 87 (02)
  • [25] Controversy around SARS-CoV-2 Reinfections
    Barreiro, Pablo
    AIDS REVIEWS, 2022, 24 (04) : 199 - 200
  • [26] Performance of Antibody Boosting Thresholds for Serological Detection of SARS-COV-2 Reinfections
    Grebe, E.
    Stone, M.
    Wright, D.
    Spencer, B.
    Akinseye, A.
    Bruhn, R.
    Biggerstaff, B.
    Custer, B.
    Jones, J.
    Busch, M.
    TRANSFUSION, 2023, 63 : 34A - 35A
  • [27] Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
    Van Elslande, Jan
    Oyaert, Matthijs
    Lorent, Natalie
    Vande Weygaerde, Yannick
    Van Pottelbergh, Gijs
    Godderis, Lode
    Van Ranst, Marc
    Andre, Emmanuel
    Padalko, Elizaveta
    Lagrou, Katrien
    Vandendriessche, Stien
    Vermeersch, Pieter
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2022, 103 (01)
  • [28] Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response
    Noble, C. C. A.
    Mcdonald, E.
    Nicholson, S.
    Biering-Sorensen, S.
    Pittet, L. F.
    Byrne, A. L.
    Croda, J.
    Dalcolmo, M.
    Lacerda, M. V. G.
    Lucas, M.
    Lynn, D. J.
    Aymerich, C. Prat
    Richmond, P. C.
    Warris, A.
    Curtis, N.
    Messina, N. L.
    JOURNAL OF INFECTION, 2025, 90 (03)
  • [29] Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study
    Demmer, Ryan T.
    Wu, Chaoqi
    Kim, John S.
    Sun, Yifei
    Balte, Pallavi
    Cushman, Mary
    Boyle, Rebekah
    Tracy, Russell P.
    Styer, Linda M.
    Bell, Taison D.
    Anderson, Michaela R.
    Allen, Norrina B.
    Schreiner, Pamela J.
    Bowler, Russell
    Schwartz, David A.
    Lee, Joyce S.
    Xanthakis, Vanessa
    Rock, Jean M.
    Bievenue, Rachel
    Pirzada, Amber
    Doyle, Margaret
    Regan, Elizabeth A.
    Make, Barry J.
    Kanaya, Alka M.
    Kandula, Namratha R.
    Wenzel, Sally E.
    Coresh, Josef
    Isasi, Carmen R.
    Raffield, Laura M.
    Elkind, Mitchell S., V
    Howard, Virginia J.
    Ortega, Victor E.
    Woodruff, Prescott
    Cole, Shelley A.
    Henderson, Joel M.
    Mantis, Nicholas J.
    Oelsner, Elizabeth C.
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (03):
  • [30] The different epidemiological questions on SARS-CoV-2 reinfections
    Procter, Simon R.
    Goncalves, Bronner P.
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2023, 52 (03) : 958 - 959
12345